On the left eye, the patient had conjunctival congestion and hyperemia, a central 2- × 2-mm corneal epithelial defect with deep stromal infiltration, endothelial plaque, moderate anterior chamber ...
Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects. According to GlobalData, Phase II drugs for Persistent Corneal ...
Crizanlizumab by Novartis for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease ...
Investigators recommend a dose of 0.2 mg/mL losartan 6 times per day for patients with a current corneal epithelial defect. Topical losartan for the treatment of scarring corneal fibrosis mediated by ...
Interfaces between the crystalline HEA and amorphous MG plates act as defect sinks, accelerating defect annihilation and minimizing structural damage. Molecular dynamics simulations revealed that ...
The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...
The Epithelial Thickness Module adds advanced thickness mapping and data insights. Ectasia View is also available and offers tracking of ectatic changes in the cornea. The FDA cleared the ...
The Epithelial Thickness Module enhances corneal assessment with advanced mapping and data insights, aiding in refractive surgery planning and corneal condition diagnosis. Ectasia View toolset ...
Sutureless amniotic membrane (ProKera) was found to be partially or completely effective in corneal ... epithelium in earlier stages of neurotrophic keratopathy without epithelial defect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback